Journal profile · Oncology
European Journal of Cancer
ISSN 0959-8049 · eISSN 1879-0852 · Elsevier Ltd · ENGLAND · Semimonthly · Founded 1965
European Journal of Cancer: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 7.84; fully open access; APC about USD 4,270; median 70 days to acceptance (111 articles, last 24 months); community-reported acceptance: about 28%; 700 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
European Journal of Cancer is published by Elsevier Ltd and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology and Lung Cancer Treatments and Mutations, together about 25.5% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Official Journal of EORTC and EUSOMAThe European Journal of Cancer (EJC) integrates preclinical, digital, translational, and clinical research in cancer, from epidemiology, carcinogenesis and biology through to innovations in cancer treatment and patient care. Within its digital oncology scope, the journal welcomes high-quality studies on artificial intelligence, machine learning, computational imaging and pathology, digital biomarkers, real-world data, electronic health record-based research, digital therapeutics, clinical decision support, large language models and other digital health applications relevant to cancer prevention, diagnosis, treatment, survivorship and patient care. The journal prioritises digital and AI studies that are clinically grounded, methodologically robust, transparently reported, appropriately validated, and that consider generalisability, reproducibility, patient safety, privacy, equity and potential sources of bias. The journal publishes original research, reviews, previews, editorial comments and correspondence.The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society of Breast Cancer Specialists (EUSOMA).
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Alexander M. M.Publisher website
Editorial board by country: none in mainland China; most named Netherlands 16, France 15, Italy 15, United Kingdom 13, Germany 10 (108 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology9.1%
- Cancer Treatment and PharmacologyMedicine8.3%
- Lung Cancer Treatments and MutationsMedicine8%
- Colorectal Cancer Treatments and StudiesMedicine6.5%
- Cancer Immunotherapy and BiomarkersMedicine5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology4.7%
- HER2/EGFR in Cancer ResearchMedicine4.6%
- Lymphoma Diagnosis and TreatmentMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.84LetPub ·
- Impact factor (publisher)
- 7.9Publisher website ·
- CiteScore 2026-06
- 10.9LetPub ·
- CiteScore (publisher)
- 10.9Publisher website ·
- SJR 2026-06
- 2.69LetPub ·
- SNIP 2026-06
- 2.16LetPub ·
- h-index
- 193LetPub ·
- h-index
- 299OpenAlex ·
- i10-index
- 11,467OpenAlex ·
- 2-year mean citedness
- 2.97OpenAlex ·
- Self-citation rate
- 2.5%LetPub ·
- Share of gold OA articles
- 43.23%LetPub ·
Volume
- Articles per year
- 377LetPub ·
Articles by year OpenAlex count · 42,102 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 656 | 202 | 183 |
| 2025 | 700 | 309 | 2,495 |
| 2024 | 1,361 | 580 | 5,401 |
| 2023 | 501 | 254 | 7,810 |
| 2022 | 1,223 | 593 | 13,846 |
| 2021 | 703 | 328 | 20,048 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
70 daysMedian, submission to acceptance · P25–P75 48 days – 95 days
- Acceptance to online
- median 5 days (111 articles)
- Submission to online
- median 76 days
- Sample
- 111 articles with submission and acceptance dates (960 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 28%LetPub ·
- Submission to first decision
- 10 daysPublisher website ·
- First decision after review
- 34 daysPublisher website ·
- Submission to acceptance
- 69 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,270 / EUR 3,990 / GBP 3,420 / JPY 529,610 | — | — | |
| Publisher website | USD 4,990 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–10
- Graphical abstract
- Optional
Article types accepted14, with length limits
- correspondence4. CorrespondenceLength not stated
- current perspectives3. Current Perspectives (max. 2,000 words)Length not stated
- editorialThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
- editorials5. EditorialsLength not stated
- letterThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…main text ≤ 1,000 words
- meta-analysisThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
- original researchThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
- original research articleThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
- perspectiveThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
- research articleThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
- reviewThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
- review articleThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
- review articles2. Review articles (max. 6,000 words)Length not stated
- systematic reviewThe primary criteria for judging which manuscripts are published are originality and high scientific/clinical significance. Manuscripts may be editorially decli…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Ethics in publishing Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Semimonthly
- Founded
- 1965
- ISSN
- 0959-8049
- Electronic ISSN
- 1879-0852
- Society / sponsor
- EORTC and EUSOMA
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about European Journal of Cancer
What CAS zone is European Journal of Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, European Journal of Cancer is in Zone 1 of Medicine, and in Zone 2 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of European Journal of Cancer?
The latest impact factor listed by LetPub is 7.84; CiteScore 10.9, h-index 299.
How long does peer review take at European Journal of Cancer?
Based on the dates recorded on 111 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 70 days (interquartile range 48–95 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 28%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of European Journal of Cancer?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–10; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of European Journal of Cancer based?
Of the 108 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Netherlands (16), France (15) and Italy (15). Counted from the institutions listed on the board page; for reference only.
Which databases index European Journal of Cancer?
According to LetPub and DOAJ records, European Journal of Cancer is indexed in SCIE and Scopus.
Is European Journal of Cancer open access, and what is the APC?
European Journal of Cancer is a fully open-access journal. APC about USD 4,270.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .